Hugh M. Davis - Search Results

Year	Number of Results
2002	2
2004	2
2005	4
2006	1
2007	5
2008	1
2009	8
2010	6
2011	6
2012	4
2013	11
2014	5
2015	6
2016	2
2017	2
2018	2
2024	0

1

Alpha-v integrins as therapeutic targets in oncology.

Nemeth JA, Nakada MT, Trikha M, Lang Z, Gordon MS, Jayson GC, Corringham R, Prabhakar U, Davis HM, Beckman RA. Nemeth JA, et al. Among authors: davis hm. Cancer Invest. 2007 Oct;25(7):632-46. doi: 10.1080/07357900701522638. Cancer Invest. 2007. PMID: 18027153 Review.

2

Rational development and utilization of antibody-based therapeutic proteins in pediatrics.

Xu Z, Davis HM, Zhou H. Xu Z, et al. Among authors: davis hm. Pharmacol Ther. 2013 Feb;137(2):225-47. doi: 10.1016/j.pharmthera.2012.10.005. Epub 2012 Oct 23. Pharmacol Ther. 2013. PMID: 23092685 Review.

3

Pharmacogenetics and pharmacogenomics of therapeutic monoclonal antibodies.

Yan L, Davis HM. Yan L, et al. Among authors: davis hm. Pharmacogenomics. 2006 Oct;7(7):961-4. doi: 10.2217/14622416.7.7.961. Pharmacogenomics. 2006. PMID: 17054405 No abstract available.

4

Clinical impact of concomitant immunomodulators on biologic therapy: Pharmacokinetics, immunogenicity, efficacy and safety.

Xu Z, Davis HM, Zhou H. Xu Z, et al. Among authors: davis hm. J Clin Pharmacol. 2015 Mar;55 Suppl 3:S60-74. doi: 10.1002/jcph.380. J Clin Pharmacol. 2015. PMID: 25707965 Review.

5

Risk-based strategy for the assessment of pharmacokinetic drug-drug interactions for therapeutic monoclonal antibodies.

Zhou H, Davis HM. Zhou H, et al. Among authors: davis hm. Drug Discov Today. 2009 Sep;14(17-18):891-8. doi: 10.1016/j.drudis.2009.05.014. Epub 2009 Jun 9. Drug Discov Today. 2009. PMID: 19520183 Review.

6

Interspecies scaling of therapeutic monoclonal antibodies: initial look.

Ling J, Zhou H, Jiao Q, Davis HM. Ling J, et al. Among authors: davis hm. J Clin Pharmacol. 2009 Dec;49(12):1382-402. doi: 10.1177/0091270009337134. Epub 2009 Oct 16. J Clin Pharmacol. 2009. PMID: 19837907 Review.

7

Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors.

Beckman RA, Weiner LM, Davis HM. Beckman RA, et al. Among authors: davis hm. Cancer. 2007 Jan 15;109(2):170-9. doi: 10.1002/cncr.22402. Cancer. 2007. PMID: 17154393 Free article. Review.

8

Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development.

Mascelli MA, Zhou H, Sweet R, Getsy J, Davis HM, Graham M, Abernethy D. Mascelli MA, et al. Among authors: davis hm. J Clin Pharmacol. 2007 May;47(5):553-65. doi: 10.1177/0091270006298360. Epub 2007 Mar 22. J Clin Pharmacol. 2007. PMID: 17379759 Review.

9

Dose selection of siltuximab for multicentric Castleman's disease.

Mayer CL, Xie L, Bandekar R, Qi M, van de Velde H, Reddy M, Qin X, Davis HM, Puchalski TA. Mayer CL, et al. Among authors: davis hm. Cancer Chemother Pharmacol. 2015 May;75(5):1037-45. doi: 10.1007/s00280-015-2720-0. Epub 2015 Mar 18. Cancer Chemother Pharmacol. 2015. PMID: 25784388

10

Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease.

Adedokun OJ, Xu Z, Gasink C, Jacobstein D, Szapary P, Johanns J, Gao LL, Davis HM, Hanauer SB, Feagan BG, Ghosh S, Sandborn WJ. Adedokun OJ, et al. Among authors: davis hm. Gastroenterology. 2018 May;154(6):1660-1671. doi: 10.1053/j.gastro.2018.01.043. Epub 2018 Feb 1. Gastroenterology. 2018. PMID: 29409871 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

55 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Results by year